The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model
Open accessAbstract
Human mesenchymal stem cells (hMSCs) can home to tumor sites and inhibit the growth of tumor cells. Little is known about the underlying molecular mechanisms that link hMSCs to the targeted inhibition of tumor cells. In this study, we investigated the effects of hMSCs on two human hepatoma cell lines (H7402 and HepG2) using an animal transplantation model, a co-culture system and conditioned media from hMSCs. Animal transplantation studies showed that the latent time for tumor formation was prolonged and that the tumor size was smaller when SCID mice were injected with H7402 cells and an equal number of Z3 hMSCs. When co-cultured with Z3 cells, H7402 cell proliferation decreased, apoptosis increased, and the expression of Bcl-2, c-Myc, proliferating cell nuclear antigen (PCNA) and survivin was downregulated. After treatment with conditioned media derived from Z3 hMSC cultures, H4702 cells showed decreased colony-forming ability and decreased proliferation. Immunoblot analysis showed that beta-catenin, Bcl-2, c-Myc, PCNA and survivin expression was downregulated in H7402 and HepG2 cells. Taken together, our findings demonstrate that hMSCs inhibit the malignant phenotypes of the H7402 and HepG2 human liver cancer cell lines, which include proliferation, colony-forming ability and oncogene expression both in vitro and in vivo. Furthermore, our studies provide evidence that the Wnt signaling pathway may have a role in hMSC-mediated targeting and tumor cell inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666
WNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763
Mesenchymal Stem Cells and Their Potential as Cardiac Therapeutics
Pittenger, M. F., & Martin, B. J. (2004) · Circulation Research · doi:10.1161/01.res.0000135902.99383.6f · Cited by 1,429
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1874 · Cited by 1,035
Notch signalling regulates stem cell numbers in vitro and in vivo
Androutsellis-Theotokis, A., Leker, R. R., Soldner, F., Hoeppner, D. J., Ravin, R., Poser, S. W., Rueger, M. A., Bae, S.-K., Kittappa, R., & McKay, R. D. G. (2006) · Nature · doi:10.1038/nature04940 · Cited by 956
Ponte, A. L., Marais, E., Gallay, N., Langonné, A., Delorme, B., Hérault, O., Charbord, P., & Domenech, J. (2007) · STEM CELLS · doi:10.1634/stemcells.2007-0054 · Cited by 947
Studeny, M., Marini, F. C., Dembinski, J. L., Zompetta, C., Cabreira-Hansen, M., Bekele, B. N., Champlin, R. E., & Andreeff, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh299 · Cited by 842
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Wnt signaling: is the party in the nucleus?
Willert, K., & Jones, K. A. (2006) · Genes & Development · doi:10.1101/gad.1424006 · Cited by 589
Research works printed but not linked: 5
- Livraghi T, Meloni F, Frosi A . Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial. Oncol Res 2005; 15:399–408. · doi:10.3727/096504005776449716
- Omuro Y, Matsumoto G, Sasaki T, et al. Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Bone Marrow Transplant 2003; 31:943–945. · doi:10.1038/sj.bmt.1703932
- Qiao L, Xu ZL, Tan X, et al. Investigation of inhibition of Wnt/β-catenin pathway in breast cancer cells mediated by Dkk-1 released from human mesenchymal stem cells. Prog Biochem Biophys 2007; 34:702–708.
- Joubert A, Bianchi P, Maritz C, et al. Influence of prostaglandin A2 on Bax, Bcl-2 and PCNA expression in MCF-7 cells. Biomed Res 2006; 27:157–162. · doi:10.2220/biomedres.27.157
- Plas E, Carroll VA, Jilch R, et al. Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer. Cytometry 2001; 46:184–189. · doi:10.1002/cyto.1104
Cited by
Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562
Nanocarbons for Biology and Medicine: Sensing, Imaging, and Drug Delivery
Panwar, N., Soehartono, A. M., Chan, K. K., Zeng, S., Xu, G., Qu, J., Coquet, P., Yong, K.-T., & Chen, X. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00099 · Cited by 555
Mesenchymal stem cells: key players in cancer progression
Ridge, S. M., Sullivan, F. J., & Glynn, S. A. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0597-8 · Cited by 526
McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45273 · Cited by 380
Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy
Hmadcha, A., Martin-Montalvo, A., Gauthier, B. R., Soria, B., & Capilla-Gonzalez, V. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00043 · Cited by 341
Mesenchymal stem cells engineered for cancer therapy
Shah, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.010 · Cited by 322
Clinical applications of mesenchymal stem cells
Kim, N., & Cho, S.-G. (2013) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2013.28.4.387 · Cited by 314
Qiao, L., Xu, Z.-L., Zhao, T.-J., Ye, L.-H., & Zhang, X.-D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.032 · Cited by 313
Self-citationMicrovesicles Derived from Human Bone Marrow Mesenchymal Stem Cells Inhibit Tumor Growth
Bruno, S., Collino, F., Deregibus, M. C., Grange, C., Tetta, C., & Camussi, G. (2013) · Stem Cells and Development · doi:10.1089/scd.2012.0304 · Cited by 309
Torsvik, A., Røsland, G. V., Svendsen, A., Molven, A., Immervoll, H., McCormack, E., Lønning, P. E., Primon, M., Sobala, E., Tonn, J.-C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1305 · Cited by 284
Kalimuthu, S., Gangadaran, P., Rajendran, R. L., Zhu, L., Oh, J. M., Lee, H. W., Gopal, A., Baek, S. H., Jeong, S. Y., Lee, S.-W., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01116 · Cited by 268
Carbon‐Based Nanomaterials for Cancer Therapy via Targeting Tumor Microenvironment
Saleem, J., Wang, L., & Chen, C. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800525 · Cited by 262
Zhuang, W.-Z., Lin, Y.-H., Su, L.-J., Wu, M.-S., Jeng, H.-Y., Chang, H.-C., Huang, Y.-H., & Ling, T.-Y. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00725-7 · Cited by 258
The roles of mesenchymal stem cells in tumor inflammatory microenvironment
Sun, Z., Wang, S., & Zhao, R. C. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-14 · Cited by 249
Self-citationMesenchymal stem cell secretome for regenerative medicine: Where do we stand?
Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 252
Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?
Haddad, R., & Saldanha-Araujo, F. (2014) · BioMed Research International · doi:10.1155/2014/216806 · Cited by 188
Mesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
“Liver cancer H7402, HepG2, HuH7, MHCC97L, H22 Human SA, human fetal derm Z3 line, human liver cancer, mouse BM Anti- or pro-proliferation, pro-apoptotic, anti-survival, pro-invasion Anti- or pro-growth, pro-metastatic [34,74, 162,163]”
BackgroundGalland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system
Wang, X., Chen, H., Zeng, X., Guo, W., Jin, Y., Wang, S., Tian, R., Han, Y., Guo, L., Han, J., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.08.006 · Cited by 126
Ko, S.-F., Yip, H.-K., Zhen, Y.-Y., Lee, C.-C., Lee, C.-C., Huang, C.-C., Ng, S.-H., & Lin, J.-W. (2015) · Stem Cells International · doi:10.1155/2015/853506 · Cited by 125
Role of MSC in the Tumor Microenvironment
Hass, R. (2020) · Cancers · doi:10.3390/cancers12082107 · Cited by 116
“Moreover, MSC isolated from the dermal tissue of an aborted human fetus and immortalized with hTERT (human telomerase reverse transcriptase) were capable to inhibit hepatoma cell line-induced tumor growth in SCID mice, which involved the WNT/β-catenin signaling pathway [89].”
BackgroundMesenchymal stem cell signaling in cancer progression
Torsvik, A., & Bjerkvig, R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.005 · Cited by 100
Potential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99
Regenerative therapy after cancer: what are the risks?
Donnenberg, V. S., Zimmerlin, L., Rubin, J. P., & Donnenberg, A. D. (2010) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2010.0352 · Cited by 95
Mesenchymal stem cells and cancer: Friends or enemies?
Hong, I.-S., Lee, H.-Y., & Kang, K.-S. (2014) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2014.01.006 · Cited by 82
Ye, H., Cheng, J., Tang, Y., Liu, Z., Xu, C., Liu, Y., & Sun, Y. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.692171 · Cited by 78
Mesenchymal stromal cells as cancer promoters
Antoon, R., Overdevest, N., Saleh, A. H., & Keating, A. (2024) · Oncogene · doi:10.1038/s41388-024-03183-1 · Cited by 75
Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells
Norozi, F., Ahmadzadeh, A., Shahrabi, S., Vosoughi, T., & Saki, N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5187-7 · Cited by 69
Ma, S., Liang, S., Jiao, H., Chi, L., Shi, X., Tian, Y., Yang, B., & Guan, F. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1836-y · Cited by 45
Influence of mesenchymal stem cells on metastasis development in mice in vivo
Meleshina, A. V., Cherkasova, E. I., Shirmanova, M. V., Klementieva, N. V., Kiseleva, E. V., Snopova, L. В., Prodanets, N. N., & Zagaynova, E. V. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0003-7 · Cited by 45
Yang, L., Zhang, Y., Cheng, L., Yue, D., Ma, J., Zhao, D., Hou, X., Xiang, R., & Cheng, P. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.135 · Cited by 39
“43,44 Therefore, we suggest that patients treated with MSCs should be followed because the potential side effects of immunosuppression induced by MSCs cannot be ignored.”
Guiho, R., Biteau, K., Grisendi, G., Taurelle, J., Chatelais, M., Gantier, M., Heymann, D., Dominici, M., & Redini, F. (2016) · International Journal of Cancer · doi:10.1002/ijc.30402 · Cited by 38
Current understanding of mesenchymal stem cells in liver diseases
Wu, M.-C., & Meng, Q.-H. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i9.1349 · Cited by 29
Zheng, H., Zou, W., Shen, J., Xu, L., Wang, S., Fu, Y.-X., & Fan, W. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0300 · Cited by 28
Su, Y., Cheng, R., Zhang, J., Qian, J., Diao, C., Ran, J., Zhang, H., & Li, L. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.10.031 · Cited by 25
LEE, S.-W., JEON, T. J., & BISWAL, S. (2015) · Oncology Reports · doi:10.3892/or.2015.3711 · Cited by 10
Metadata
- Authors
- Qiao, L., Xu, Z., Zhao, T., Zhao, Z., Shi, M., Zhao, R. C., Ye, L., & Zhang, X.
- Venue
- Cell Research
- Published
- 2008-03-25
- Volume
- 18
- Issue
- 4
- Pages
- 500-507
- ISSN
- 1001-0602 (ISSN-L)
- 1748-7838
- OpenAlex
- W2083808914
- Cited by
- 388
- References
- 36
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.